AltrixBio
Cambridge
About AltrixBio
AltrixBio is a developer of therapeutic drugs designed for controlled gastrointestinal targeting. They treat patients by providing duodenal isolation similar to gastric bypass, enabling patients with an oral drug that replicates the metabolic success of bariatric surgery and is quite financially feasible than surgery.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $6.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2025)
- Website: altrixbio.com
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/altrixbio-92495 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.